Last 48 quarters of trend data · Healthcare · Ophthalmology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 0.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.86 | 0.00 | 3.39 | 2.42 | 7.04 | 6.37 | 4.16 | 5.41 | 4.18 | 3.77 | 2.00 | 1.71 | 1.73 | 3.20 | 3.80 | 4.25 | 2.70 | 1.92 | 1.34 | 1.36 | 1.13 |
| — | -100.0% | -18.5% | -55.3% | +68.5% | +69.0% | +107.9% | +216.1% | +141.0% | +17.7% | -47.3% | -59.7% | -35.7% | +66.4% | +184.1% | +212.7% | +139.3% | -17.0% | -49.2% | -68.4% | -74.7% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | 103.80 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -58.7% | -21.4% | -13.6% | -8.0% | -13.8% | -14.7% | -16.4% | -14.8% | -20.3% | -16.5% | -15.9% | -6.9% | -3.9% | -6.5% | -6.7% | -10.8% | -8.2% | -8.7% | -9.8% | -8.5% | -7.4% |
| — | -45.3% | +17.1% | +45.8% | +31.8% | +10.7% | -3.2% | -112.9% | -417.3% | -154.5% | -136.5% | +36.0% | +52.5% | +25.2% | +31.0% | -27.9% | -11.2% | -24.2% | -17.4% | +30.4% | +57.8% | |
| ROA | -38.3% | -17.3% | -9.6% | -5.0% | -8.6% | -9.4% | -11.0% | -10.0% | -14.2% | -12.4% | -12.6% | -5.6% | -3.2% | -5.4% | -5.6% | -8.9% | -7.0% | -7.4% | -8.4% | -7.4% | -6.6% |
| — | -83.6% | +12.8% | +50.4% | +39.5% | +23.9% | +13.0% | -79.9% | -343.0% | -129.8% | -127.1% | +37.5% | +53.8% | +27.4% | +33.9% | -21.3% | -6.0% | -18.8% | -13.4% | +24.8% | +50.1% | |
| ROIC | -245.8% | — | — | — | — | -34.2% | -26.1% | -25.8% | -38.6% | -32.1% | -38.9% | -73.3% | — | — | — | -229.1% | -28.5% | -18.7% | -22.8% | -62.6% | — |
| — | — | — | — | — | -6.8% | +32.8% | +64.8% | — | — | — | +68.0% | — | — | — | -265.8% | — | — | +97.4% | +99.9% | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.35 | 0.01 | 0.00 | 0.37 | 0.35 | 0.32 | 0.28 | 0.24 | 0.22 | 0.18 | 0.16 | 0.14 | 0.13 | 0.13 | 0.12 | 0.12 | 0.11 | 0.10 | 0.09 | 0.08 | 0.08 |
| — | -95.9% | -98.7% | +50.3% | +62.8% | +72.0% | +76.9% | +77.3% | +64.9% | +39.5% | +27.9% | +17.6% | +22.7% | +33.9% | +36.0% | +40.9% | +38.2% | +36.4% | +38.2% | -31.8% | -70.1% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.58 | 5.45 | 4.91 | 2.72 | 2.58 | 2.72 | 2.86 | 6.49 | 5.59 | 6.80 | 4.55 | 6.50 | 6.64 | 6.81 | 9.96 | 10.50 | 11.78 | 7.83 | 12.36 | 13.60 | 19.77 |
| — | +100.3% | +71.4% | -58.0% | -53.9% | -60.0% | -37.1% | -0.1% | -15.7% | -0.1% | -54.3% | -38.1% | -43.7% | -13.0% | -19.4% | -22.8% | -40.4% | -62.1% | -64.3% | +2.5% | +195.4% | |
| Quick Ratio | 2.58 | 5.45 | 4.91 | 2.72 | 2.58 | 2.72 | 2.86 | 6.49 | 5.59 | 6.80 | 4.55 | 6.50 | 6.64 | 6.81 | 9.96 | 10.50 | 11.78 | 7.83 | 12.36 | 13.60 | 19.77 |
| — | +100.3% | +71.4% | -58.0% | -53.9% | -60.0% | -37.1% | -0.1% | -15.7% | -0.1% | -54.3% | -38.1% | -43.7% | -13.0% | -19.4% | -22.8% | -40.4% | -62.1% | -64.3% | +2.5% | +195.4% | |
| Interest Coverage | -16.76 | -9443.55 | -236967.39 | -6.37 | -12.60 | -15.16 | -19.75 | -19.54 | -32.57 | -30.53 | -34.28 | -15.21 | -8.24 | -14.20 | -16.05 | -30.79 | -27.00 | -33.91 | -42.33 | -40.35 | -37.15 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ALDX stock.
Aldeyra The's current P/E is 0.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Aldeyra The's business trajectory between earnings reports.